27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Sage Therapeutics Inc (NASDAQ:SAGE) shares are trading lower Monday after the company announced the FDA issued a Complete Response Letter (CRL) for one of the company's New Drug Applications.
What To Know: Sage Therapeutics said the FDA approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression, but issued a CRL for its NDA for zuranolone for treatment of adults with major depressive disorder.
The letter said Sage's application didn't provide substantial evidence of effectiveness to support the approval of zuranolone as a major depressive disorder treatment. The FDA determined that additional studies will be needed.
"In regard to the CRL for MDD, we are highly disappointed for patients, particularly amid the current mental health crisis and millions of people with MDD struggling to find symptom relief," said Barry Greene, CEO of Sage Therapeutics.
See Also: Merck Is Driving Ginkgo Bioworks Stock Higher Monday: What's Going On?
SAGE Price Action: Sage shares were down 49.4% at $18.26 at the time of publication, according to Benzinga Pro.
Photo: Pexels from Pixabay.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!